← Eichor
Condition: Relapsed Refractory Primary Central Nervous System Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Primary Central Nervous System Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07137494Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/Phase 2 · 5 location(s) · Tong Chen, MD · NCT05698147A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06556199A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ
NA · 1 location(s) · Ruijin Hospital · NCT07191431Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07416890IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 3 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07104032DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05209620A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT070828683'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif
Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT07523737NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL
Phase 2 · 10 location(s) · NOBO Medicine · NCT06737250Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07074470Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Phase 1/Phase 2 · 4 location(s) · Dana-Farber Cancer Institute · NCT04421560Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06213636CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04186520Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Phase 2 · 1 location(s) · Baptist Health South Florida · NCT05681195A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 16 location(s) · Nurix Therapeutics, Inc. · NCT04830137Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04961515T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/Phase 2 · 2 location(s) · Estrella Biopharma, Inc. · NCT06343311The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervo
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931328CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/Phase 2 · 35 location(s) · Children's Oncology Group · NCT04870944Phase Ib Clinical Study of Keynatinib
Phase 1 · 4 location(s) · Medolution Ltd. · NCT04807881Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Phase 2 · 1 location(s) · Hyungwoo Cho · NCT07062627A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary
Phase 1/Phase 2 · 45 location(s) · Curis, Inc. · NCT03328078Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Phase 2 · 13 location(s) · The Lymphoma Academic Research Organisation · NCT06931652
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.